1897 related articles for article (PubMed ID: 18684704)
1. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
[TBL] [Abstract][Full Text] [Related]
5. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens.
Poulakou G; Kontopidou FV; Paramythiotou E; Kompoti M; Katsiari M; Mainas E; Nicolaou C; Yphantis D; Antoniadou A; Trikka-Graphakos E; Roussou Z; Clouva P; Maguina N; Kanellakopoulou K; Armaganidis A; Giamarellou H
J Infect; 2009 Apr; 58(4):273-84. PubMed ID: 19344841
[TBL] [Abstract][Full Text] [Related]
6. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii.
Schafer JJ; Goff DA; Stevenson KB; Mangino JE
Pharmacotherapy; 2007 Jul; 27(7):980-7. PubMed ID: 17594203
[TBL] [Abstract][Full Text] [Related]
7. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
Garrison MW; Neumiller JJ; Setter SM
Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
9. Tigecycline: first of a new class of antimicrobial agents.
Rose WE; Rybak MJ
Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
[TBL] [Abstract][Full Text] [Related]
10. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Tanaseanu C; Bergallo C; Teglia O; Jasovich A; Oliva ME; Dukart G; Dartois N; Cooper CA; Gandjini H; Mallick R; ;
Diagn Microbiol Infect Dis; 2008 Jul; 61(3):329-38. PubMed ID: 18508226
[TBL] [Abstract][Full Text] [Related]
11. Tigecycline: a novel glycylcycline antibiotic.
Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.
Garrison MW; Mutters R; Dowzicky MJ
Diagn Microbiol Infect Dis; 2009 Nov; 65(3):288-99. PubMed ID: 19733459
[TBL] [Abstract][Full Text] [Related]
13. Tigecycline for the treatment of Acinetobacter infections: a case series.
Gallagher JC; Rouse HM
Ann Pharmacother; 2008 Sep; 42(9):1188-94. PubMed ID: 18614749
[TBL] [Abstract][Full Text] [Related]
14. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients.
Falagas ME; Rafailidis PI; Matthaiou DK; Virtzili S; Nikita D; Michalopoulos A
Int J Antimicrob Agents; 2008 Nov; 32(5):450-4. PubMed ID: 18768302
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
[TBL] [Abstract][Full Text] [Related]
17. Tigecycline: a new glycylcycline antimicrobial.
Townsend ML; Pound MW; Drew RH
Int J Clin Pract; 2006 Dec; 60(12):1662-72. PubMed ID: 17109673
[TBL] [Abstract][Full Text] [Related]
18. Tigecycline: in-vitro performance as a predictor of clinical efficacy.
Hawkey P; Finch R
Clin Microbiol Infect; 2007 Apr; 13(4):354-62. PubMed ID: 17359318
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
Bradford PA; Weaver-Sands DT; Petersen PJ
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S315-32. PubMed ID: 16080070
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
